Using MRI to guide radiotherapy for cancer treatment
Official title: Northern Alberta Linac-MR Image-Guided Human Clinical Trials - 2
Run by AHS Cancer Control Alberta · NCT05413473 · Data updated 2026-11-12
This study is testing if using MRI to guide radiotherapy can improve cancer treatment for adults compared to traditional methods.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 99 (estimated) |
| Sponsor | AHS Cancer Control Alberta Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Edmonton, Alberta) |
| Status | Recruiting |
| Started | February 8, 2023 |
| Main results expected | March 31, 2029 |
| Study ends | January 2030 |
| Registry record updated | November 5, 2026 |
| Trial ID | NCT05413473 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who are fit for external beam radiation therapy.
✕Probably not a fit
Patients with contraindications for MRI or those unable to provide informed consent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the feasibility of using MR-guided radiotherapy with the Alberta linac-MR P3 system in adult cancer patients. The study progresses through four stages, starting with palliative care and advancing to curative techniques, utilizing MRI instead of traditional CT scans for treatment planning and delivery. Participants will undergo standard radiotherapy procedures while being monitored for adverse events and treatment effectiveness over a follow-up period of up to five years. The goal is to determine the acceptability and potential advantages of this innovative approach in cancer treatment.
Why it matters
Potential benefit: If successful, this approach could lead to more precise and effective radiotherapy treatments for cancer patients.
How similar studies have gone: While the use of MRI in radiotherapy is being explored, this specific approach with the Alberta linac-MR P3 system is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults ≥ 18 years of age * Patients deemed fit to undergo external beam radiation therapy by their attending radiation oncologist * Accessible for follow-up Exclusion Criteria: * Patients with contraindications for MRI * Patients who are unable to lie flat and still for the duration of the expected scan acquisition and treatment * Patients who are unable to provide informed consent * Patients with clinically significant inferior treatment plans compared to standard CT based external beam plans. For example, plans that generate hot spots of \> 110% or other unacceptable treatment plans that would not otherwise arise with standard CT based external beam plans. * Pregnancy
Where it's running
-
Cross Cancer Institute
Edmonton, Alberta, Canada Recruiting
Study contacts
- Principal investigator: Nawaid Usmani, MD — Cross Cancer Institute, Alberta Health Services
- Study coordinator: Nawaid Usmani, MD
- Email: Nawaid.Usmani@ahs.ca
- Phone: 780-432-8518
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Personalized two-fraction radiation for prostate cancer
This study tests a two-fraction, MRI-guided radiation approach for intermediate- to high-risk prostate cancer to see if targeting nodules can be safely effective.
-
Morning vs Flexible Timing Pembrolizumab in Metastatic Non-Small Cell Lung Cancer
This study tests whether giving pembrolizumab in the morning is better or the same as standard timing for people with metastatic non-small cell lung cancer who are eligible for this treatment.
-
Inhaled budesonide to prevent recurrent checkpoint inhibitor–related pneumonitis
This study tests whether adding inhaled budesonide to usual care can prevent recurrence of pneumonitis in adults who developed grade 2 or higher lung inflammation from checkpoint inhibitor immunotherapy.
-
Vedolizumab to prevent ICI-related diarrhea or colitis in cancer patients
This study tests whether vedolizumab can prevent immune checkpoint inhibitor–related diarrhea or colitis in adults with unresectable or metastatic melanoma, lung, or kidney cancer starting immunotherapy.
-
Using SBRT to treat liver metastases from colorectal cancer after initial treatment
This study is testing if a special type of radiation therapy can help people with liver tumors from colorectal cancer feel better after their initial treatment.
-
Mesalamine to prevent colitis from ipilimumab plus nivolumab
This trial will try giving mesalamine to adults with advanced melanoma who are starting ipilimumab plus nivolumab to see if it lowers the chance and severity of immune-related diarrhea and colitis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.